John Baldoni, PhD has over 41 years of experience in the pharmaceutical industry. He spent 29 years at GSK R&D, 11 years on its Executive Leadership Team as SVP of Platform Technology and Science, which comprised about 40% of R&D headcount. This organization supported development of small molecules, biopharmaceuticals and cell and gene therapy modalities from discovery through commercialization. After stepping away from that leaderhip role, John started the first AI-driven drug discovery unit at GSK in 2017. After retiring from GSK in 2019 he spent a year as the Chief Technology Officer of a stealth AI-enabled drug discover startup. Currently, John is an independent consultant. His clients include emerging, cutting edge drug and diagnostic discovery healthcare companies and established companies seeking new strategic direction. John has participated in the research and development of scores of commercial products. He is a proponent of seeking, integrating and implementing innovative approaches to drug discovery and development. He conceptualized and is currently senior advisor to the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium – an open membership, public/private partnership. John was the first Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare, an organization formed to foster improved healthcare by responsible investment, invention and innovation in artificial intelligence. John received his PhD from Penn State University in biological chemistry in 1980.
Send us an email to learn about our partnership and career opportunities or for additional questions.contact us